Genetic Engineering & Biotechnology News

06/01/2026

AI-Powered Pan-Cancer Map Reveals Tertiary Lymphoid Structures

Researchers at UT MD Anderson Cancer Center say future studies should investigate whether TLS-informed stratification can guide clinical trial design or therapeutic modulation strategies. Led by Linghua Wang, MD, PhD, the team developed scalable artificial intelligence (AI) frameworks to detect, profile and classify TLSs from spatial omics data and routine pathology slides.

The University of Texas at Austin

Researchers say future studies should investigate whether TLS-informed stratification can guide clinical trial design or therapeutic modulation strategies.

06/01/2026

Don't Miss Out! From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies

Broadcast Date: Thursday, June 4, 2026
Time: 10:00 PDT, 13:00 EDT, 17:00 GMT

In this GEN webinar, Joseph Shultz (vice president of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (vice president of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year.

Register for this free webinar sponsored by Asimov: https://hubs.li/Q04ggkQw0

06/01/2026

Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration

Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, through a collaboration that could generate up to $10.5 billion for the Chinese biotech.

Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, through a collaboration that could generate up to $10.5 billion for the Chinese biotech.

05/29/2026

Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer

The data from The Wistar Institute, Temple University, and their collaborators showed elevated levels of the metabolite αKG improved DNA repair, and blocking it made the cancer cells more sensitive to treatment.

The data showed elevated levels of the metabolite αKG improved DNA repair, and blocking it made the cancer cells more sensitive to treatment.

05/29/2026

Mark Your Calendar! Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs

Register for this free webinar sponsored by Countable Labs: https://hubs.li/Q04hkT4k0

05/29/2026

Gene Editing at Scale: Clinic Seeks Generalizable Therapies

End-to-end pipelines and regulatory advances aim to expand gene editing to broad patient populations. In this article from our May Issue GEN's Fay Lin, PhD includes feedback from:

Ajay Gannerkote, president of Integrated DNA Technologies
Sadik Kassim, PhD, CTO of Genomic Medicines at Danaher Corporation
Amy Pooler, PhD, CSO of ElevateBio
Ben Kleinstiver, PhD, associate investigator at Massachusetts General Hospital
Edward Kaye, MD, CEO and director of Aurora Therapeutics
Maher Masoud, CEO of MaxCyte

End-to-end pipelines and regulatory advances aim to expand gene editing to broad patient populations.

05/28/2026

PRINCE: A Small-Molecule Switch for Safer Gene Editing

Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing. Its compact version, Little Prince, showed therapeutic potential in mouse models of cholesterol disease and macular degeneration.

Chinese Academy of Sciences, Shenzhen University, Fudan University

Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing.

05/28/2026

Mark Your Calendar! From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies

Register for this free webinar sponsored by Asimov: https://hubs.li/Q04gcVpQ0

05/28/2026

Biohub Releases Protein Biology World Model to Address Disease

The latest update to the ESM protein language model family has expanded capabilities in binder design and protein function mapping for therapeutic discovery. The release comes just seven months after Biohub recruited the team behind EvolutionaryScale.

The latest update to the ESM protein language model series supports binder design and protein function mapping for therapeutic discovery.

05/27/2026

AI Model Predicts Cancer Treatment Response from Tumor Genotype

Researchers at the UC San Diego developed an AI foundational model, MutationProjector, that can translate a tumor’s complex genetic profile into predictions about how that cancer may respond to treatment, and provide insight into why those predictions are made. “Our goal with MutationProjector was to build a general-purpose model that can learn from tens of thousands of tumor genomes and turn those mutation patterns into more precise predictions about treatment responser,” said Trey Ideker, PhD, who also holds a second appointment at UC San Diego Jacobs School of Engineering and is a member of UC San Diego Moores Cancer Center.

Researchers suggest MutationProjector offers a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes.